[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100459202":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":34,"responsibleParty":76,"collaborators":19,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":80,"sex":86,"minAge":87,"maxAge":19,"enrollmentInfo":88,"targetDuration":19,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":99,"overallStatus":37,"whyStopped":19,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de Saint Etienne","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with multiple myeloma","EXPERIMENTAL","Adult patient, over 18 years old, with newly diagnosed multiple myeloma, indication of chemotherapy.",[13],"Other: Blood samples",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"Blood samples","Peripheral blood sampling will be performed at different time points of the study, for a total volume of 20-40 mL:\n\n* Sampling before MM treatment,\n* Sampling during MM treatment (at 3 months post-initiation if no autograft or before autograft),\n* Only for Patients treated with Apixaban or Eliquis®, 2 additional samplings during MM treatment for pharmacokinetics analysis.",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Emilie Chalayer, MD","CHU de Saint-Etienne","PRINCIPAL_INVESTIGATOR",[26,31],{"name":22,"role":27,"phone":28,"phoneExt":29,"email":30},"CONTACT","04 77 91 70 00","+33","emilie.chalayer@chu-st-etienne.fr",{"name":32,"role":27,"phone":19,"phoneExt":19,"email":33},"Elisabeth Daguenet, PhD","elisabeth.daguenet@icloire.fr",[35,52],{"facility":36,"status":37,"city":38,"state":19,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Hospices Civils de Lyon","RECRUITING","Lyon","69495","France","FR",{"type":43,"coordinates":44},"Point",[45,46],4.84789,45.74906,{"lat":46,"lon":45},[49,51],{"name":50,"role":27,"phone":19,"phoneExt":19,"email":19},"Lionel Karlin, MD",{"name":50,"role":24,"phone":19,"phoneExt":19,"email":19},{"facility":23,"status":37,"city":53,"state":19,"zip":54,"country":40,"countryCode":41,"cosmosGeoPoint":55,"geoPoint":59,"contacts":60},"Saint-Etienne","42055",{"type":43,"coordinates":56},[57,58],4.39,45.43389,{"lat":58,"lon":57},[61,62,63,66,68,70,72,74],{"name":22,"role":27,"phone":19,"phoneExt":19,"email":19},{"name":22,"role":24,"phone":19,"phoneExt":19,"email":19},{"name":64,"role":65,"phone":19,"phoneExt":19,"email":19},"Denis Guyotat, PhD","SUB_INVESTIGATOR",{"name":67,"role":65,"phone":19,"phoneExt":19,"email":19},"Ludovic Fouillet, MD",{"name":69,"role":65,"phone":19,"phoneExt":19,"email":19},"Caroline Lejeune, MD",{"name":71,"role":65,"phone":19,"phoneExt":19,"email":19},"Karine Augeul-Meunier, MD",{"name":73,"role":65,"phone":19,"phoneExt":19,"email":19},"Thierry Thomas, PhD",{"name":75,"role":65,"phone":19,"phoneExt":19,"email":19},"Karima Boussoualim, MD",{"type":77,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100459202","biomarkers-in-multiple-myeloma-100459202",false,"NCT05259553","Biomarkers in Multiple Myeloma","Evaluation of Predictive Biomarkers in de Novo Multiple Myeloma on the Onset of Venous Thromboembolism, Its Impact on Clinical Outcome and Thromboprophylaxis (VESICOM)","VESICOM","Inclusion Criteria:\n\n* Patient affiliated to a social security regimen or beneficiary of the same\n* Signed written informed consent form\n* Confirmed diagnosis of de novo multiple myeloma, non-previously treated and requiring treatment.\n\nExclusion Criteria:\n\n* Pregnant women\n* Patient under guardianship or deprived of his liberty or any condition that may affect the patient's ability to understand and sign the informed consent\n* Refusing participation\n* Patient whose follow-up or life expectancy is less than 6 months.","ALL","18 Years",{"count":89,"type":90},70,"ESTIMATED","INTERVENTIONAL",[93],"NA","The association between multiple myeloma (MM) and venous thromboembolism (VTE) is well known. Indeed, the incidence of VTE is increased in patients with newly diagnosed MM and in patients treated by immunomodulatory drugs in combination with glucocorticoids. Moreover, the clinical outcome of MM is supposed to be correlated to the risk of thrombosis. At the biological level, a number of hemostasis abnormalities participate in increasing VTE incidence. Yet, data on predictive biomarkers linked to VTE are limited.",[96,97,98],"Hematological Patients","Newly Diagnosed Multiple Myeloma","Chemotherapy",[100,101,102,103],"hematology","multiple myeloma","chemotherapy","thromboprophylaxis","2025-04-07",{"date":106,"type":107},"2025-04-09","ACTUAL",{"date":109,"type":107},"2022-05-20",{"date":111,"type":90},"2027-10-30",{"name":5,"class":6},2]